Conmed (CNMD) Reports Q2 Earnings: What Key Metrics Have to Say

For the quarter ended June 2026, Conmed (CNMD) reported revenue of $343.49 million, up 0.3% over the same period last year. EPS came in at $1.38, compared to $1.15 in the year-ago quarter.

The reported revenue represents a surprise of +1.85% over the Zacks Consensus Estimate of $337.24 million. With the consensus EPS estimate being $1.10, the EPS surprise was +25.46%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Conmed performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Geographic Revenue- International: $168.1 million versus $153.69 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +10.8% change.
• Geographic Revenue- Domestic: $175.4 million compared to the $183.55 million average estimate based on two analysts. The reported number represents a change of -8% year over year.
• Net Sales- Single-use Products: $295.1 million versus the two-analyst average estimate of $286.83 million. The reported number represents a year-over-year change of -0.9%.
• Net Sales- General Surgery: $191.2 million compared to the $186.32 million average estimate based on two analysts. The reported number represents a change of -5.2% year over year.
• Net Sales- Orthopedic Surgery: $152.3 million versus the two-analyst average estimate of $150.93 million. The reported number represents a year-over-year change of +8.2%.
• Net Sales- Capital Products: $48.4 million versus the two-analyst average estimate of $50.42 million. The reported number represents a year-over-year change of +8.8%.

View all Key Company Metrics for Conmed here>>>

Shares of Conmed have returned +35.2% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research